Skip to main content
Premium Trial:

Request an Annual Quote

IGA Licenses KeyGene's Sequence-based Genotyping Technology

NEW YORK (GenomeWeb) – IGA Techology Services has licensed KeyGene's sequence-based genotyping technology for use in certain fields, the firms said today.

As part of the deal, IGA has gained a non-exclusive license for the commercial offering and use of KeyGene's technology, which includes restriction-site-associated DNA sequencing, genotyping-by-sequencing, and related methods for discovering and scoring genetic markets without genome sequence information. The firms said that the technology provides a "very powerful" method of characterizing breeding germplasm diversity and developing markers for improving agronomic traits.

Financial and other terms of the agreement were not disclosed.

KeyGene CSO Michiel van Eijk said in a statement that the ability to carry out genetic biomarker discovery and genotyping simultaneously is gaining widespread use in "a huge range of species" and today's deal "accelerates the genetic improvement of our crops, farm animals, and microorganisms."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.